NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 501
- Registration Number
- NCT01207414
- Locations
- 🇺🇸
Comprehensive Neuroscience, Fresh Meadows, New York, United States
🇺🇸Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States
🇺🇸The Hospital of Central Connecticut, New Britain, Connecticut, United States
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 138
- Registration Number
- NCT01199861
- Locations
- 🇨🇭
Novartis Investigational Site, Basel, Switzerland
🇬🇧Novartis Investigative Site, Stoke-on-Trent, United Kingdom
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 161
- Registration Number
- NCT01196546
- Locations
- 🇹🇭
Phamongkutklao Hospital, Bangkok, Thailand
🇹🇭Siriraj Hospital, Bangkok, Thailand
🇹🇭Fort Suranaree Hospital, Nakhon Ratchasima, Thailand
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 88
- Registration Number
- NCT01193907
- Locations
- 🇧🇪
Center for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk (Antwerp), Belgium
Glycemic Holter Study (Continuous Glucose Monitoring) -
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 36
- Registration Number
- NCT01193296
- Locations
- 🇫🇷
Investigative Site, Venissieux, France
Certoparin in Renal Patients Undergoing Hemodialysis
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 109
- Registration Number
- NCT01179620
- Locations
- 🇩🇪
Novartis Investigative Site Magdeburg, Magdeburg, Germany
🇩🇪Novartis Investigative Site Flensburg, Flensburg, Germany
🇩🇪Novartis Investigative Site Kronach, Kronach, Germany
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 564
- Registration Number
- NCT01167153
- Locations
- 🇨🇳
Novartis Pharmaceuticals, Beijing, China
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis
- Registration Number
- NCT01167335
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Epilepsy Care Specialists, S.C., Milwaukee, Wisconsin, United States
🇪🇸Novartis Investigative Site, Barcelona, Spain
Zoledronic Acid in MS-patients With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 29
- Registration Number
- NCT01166178
- Locations
- 🇩🇪
Novartis Investigative Site, Siegen, Germany
🇩🇪Novartis investigative site, Stade, Germany
Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 288
- Registration Number
- NCT01160094
- Locations
- 🇸🇦
Novartis Investigative Site, Riyadh, Saudi Arabia